ki:elements

AI-driven speech biomarkers for

cognition

ki:e SB-C

SB-C by ki:elements:

smarter, scalable

Digital Cognitive Assessments (DCAs) for clinical trials

Alzheimer's clinical trials are evolving, so should your tools

SB-C is an AI-driven, speech-based digital cognitive assessment that delivers faster recruitment, better patient stratification, and automated monitoring, designed specifically for clinical trials in Alzheimer’s disease and other neurodegenerative disorders.

SB-C empowers your study with speech biomarkers that are:

OBJECTIVE AND AUTOMATED

Remove subjectivity and variability with consistent, high-quality scoring—anytime, anywhere.

VALIDATED AND REGULATORY-READY

Developed with pharma partners and supported by over 30 peer-reviewed publications.

FASTER AND MORE SCALABLE

Expand recruitment beyond traditional sites with a patient-friendly, inclusive, <10 minute phone call.

COST-EFFECTIVE WITHOUT COMPROMISE

Lower operational costs and reduce screen failure rates while increasing sensitivity to cognitive decline.

FLEXIBLE FOR MODERN TRIAL DESIGNS

Support adaptive protocols with tools designed for your needs.

EFFORTLESSLY INTEGRATED

Fit into existing workflows without added burden on sites or patients. Use it out-of-the-box with our Mili System or integrate into third party systems.

V3

guided

-–

clinically

proven
Validation based on large cohorts across Europe following approved methodology from the V3 framework of the Digital Medicine Society (DiME)
Clear-cut differentiation among healthy controls, MCI and Dementia patients.
High correlation with clinical cognition rating anchors.
Strong links with AD cerebrospinal fluid markers, such as aBeta and pTau

Validation of the Remote Automated ki:e Speech Biomarker for Cognition in Mild Cognitive Impairment: Verification and Validation following DiME V3 Framework

Tröger et al. (2022) | doi: 10.1159/000526471

Read the publication
Use case scenario:

pre-screening

in Alzheimer’s Disease

Enrollment as a key barrier for AD trials

80%
of trials fail to meet enrolment timelines
30%
of clinical trial’s timeline is spent on patient recruitment
$5.9B

spent annually on clinical trial recruitment

5%
or less of potential candidates enrolled in clinical trials
Using ki:e SB-C will significantly

reduce the number of candidates

invited to sites for screening and

improve successful screen-in rate.

Screening for Mild Cognitive Impairment Using a Machine Learning Classifier and the Remote Speech Biomarker for Cognition: Evidence from Two Clinically Relevant Cohorts

Schäfer et al. (2023) | doi: 10.3233/JAD-220762

Read the publication

Case Study by Roche & DATAcc: Estimating the benefits of digital and plasma-based pre-screening in Alzheimer’s Disease trial recruitment

Read the case study
Ready to use SB-C in

your

study?
Partner with us